Abstract Objective To study the correlation between Alzheimer’s disease (AD) and type two diabetes mellitus (T2DM). Methods One hundred and fifty senile patients with AD first hospitalized in Department of Internal Neurology of Jinqiu Hospital of Liaoning Province from 2017 to 2020 were selected. According to whether combined with T2DM and the course of disease, they were divided into 84 cases in non-T2DM group, 29 cases in T2DM less than or equal to five years group and 37 cases in T2DM more than five years group. The basic data and cognitive function scores of each group were observed. The patients with AD complicated with T2DM were divided into 43 cases in group A and 23 cases in group B according to whether to control blood glucose or not, the course of AD and the score of cognitive function were observed. The effects of the course of T2DM and the level of fasting blood glucose (FBG) on the course of AD and cognitive function were analyzed. Results Body mass index, incidence of stroke, FBG and course of AD in non-T2DM group, T2DM less than or equal to five years group, and T2DM more than five years group were compared, and the differences were statistically significant (P ＜ 0.05). Mini-mental state scale (MMSE), activity of daily living scale (ADL) and AD pathological behavior scale (BEHAVE-AD) scores in non-T2DM group, T2DM less than or equal to five years group, and T2DM more than five years group were compared, the differences were statistically significant (P ＜ 0.05). Compared with group A, the course of AD in group B was prolonged, FBG levels and glycosylated hemoglobin increased, MMSE score decreased, Alzheimer’s disease assessment scale-congnitive score, BEHAVE-AD score, and ADL score increased, and the differences were statistically significant (P ＜ 0.05). The course of T2DM and FBG level were influencing factors of the course of AD, MMSE score, BEHAVE-AD, and ADL score (P ＜ 0.05). Conclusion Patients with AD complicated with T2DM have a long course of AD and a significant decline in cognitive function. Long course T2DM and hyperglycemia can promote the progress of AD. Therefore, if T2DM is found early in AD patients, blood glucose should be controlled in time, which may delay the progress of AD.
ZHANG Shuyan SUN Shuning. Research analysis of the correlation between Alzheimer’s disease and type two diabetes mellitus[J]. 中国医药导报, 2022, 19(20): 53-57.
[1] 窦凯昕，谭兰，郁金泰.阿尔茨海默病的风险因素及预防[J].中华行为医学与脑科学杂志，2019，28（4）：305-310.
[2] Li Y，Teng D，Shi X，et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association：national cross sectional study [J]. BMJ，2020，369：m997.
[3] Steen E，Terry BM，Rivera EJ，et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease-is this type 3 diabetes? [J] J Alzheimer Dis，2005，7（1）：63-80.
[4] Alzheimer’s Association. 2014 Alzheimer’s disease facts and figures [J]. Alzheimer Dement，2014，10（2）：e47-e92.
[5] Xue M，Xu W，Qu YN，et al. Diabetes mellitus and risks of cognitive impairment and dementia：a systematic review and meta-analysis of 144 prospective studies [J]. Agexing Res Rev，2019，55：100944.
[6] American Psychiatric Association. Diagnostic and statistical manual of mental disorders.DSM-Ⅳ-TR [M]. 4th ed. Washington DC：American Psychiatric Publishing，2002： 109-116.
[7] 贾建平，王萌华，张振馨，等.中国痴呆与认知障碍诊治指南（三）：神经心理评估量表的选择[J].中华医学杂志，2011，91（11）：735-741.
[8] Jagust W，Harvey D，Mungas D，et al. Central obesity and the aging brain [J]. Arch Neurol，2005，62（10）：1545-1548.
[9] Akhtar A，Sah SP. Insulin signaling pathway and related molecules：role in neurodegeneration and Alzheimer’s disease [J]. Neurochem Int，2020，135：104707.
[10] Shieh JC，Huang PT，Lin YF. Alzheimer’s disease and diabetes：insulin signaling as the bridge linking two pathologies [J]. Mol Neurobiol，2020，57（4）：1966-1977.
[11] Kong Y，Wang F，Wang J，et al. Pathological mechanisms linking diabetes mellitus and Alzheimer’s disease：the receptor for advanced glycation end products （RAGE） [J]. Front Aging Neurosci，2020，12：217.
[12] 王莹，付羽鸿.2型糖尿病胰岛素抵抗与阿尔茨海默病[J].临床与病理杂志，2021，40（3）：673-677.
[13] Andreetto E，Yan LM，Tatarek-Nossol M，et al. Identification of hot regions of the Abeta-IAPP ìnteraction interface as high-affinity hinding sites in hoth cross-and self-association [J]. Angew Chem Int Ed Engl，2010，49（17）：3081-3085.
[14] GoLdwaser EL，Acharya NK，Sarkar A，et al. Breakdown of the cerebrovasculature and blood-brain barrier：a mechanistic link between diabetes mellitus and ALzheimer’s disease [J]. J ALzheimers Dis，2016，54（2）：445-456.
[15] 伏彩霞，尚天明，马宝山.阿尔茨海默病患者炎症因子、氧化应激与胰岛素抵抗的相关性分析[J].检验医学与临床，2019，16（7）：939-942.
[16] Stefanova NA，Muraleva NA，Maksimova KY，et al. An antioxidant specificallly targeting mitoccondria delays progression of Alzheimers’s disease-like pathology [J]. Aging，2016，8（11）：2713-2733.
[17] 辛宁，陈健康，陈艳，等.多芯片联合分析2型糖尿病发病相关基因及其与阿尔茨海默病的关系[J].中国医科大学学报，2020，49（12）：1106-1111，1117.
[18] Gudala K，Bansal D，Schifano F，et al. Diabetes mellitus and risk of dementia：a meta-analysis of prospective observational studies [J]. J Diabetes Investig，2013，4（6）：640-650.
[19] 王飞，罗剑锋，丁玎，等.糖尿病对老年人总体认知功能水平及各认知领域的影响[J].中国临床神经科学，2019， 27（1）：29-38.
[20] Craft S，Claxton A，Baker LD，et al. Effects of regular and long-acting insulin on cognition and Alzheimer’s disease biomarkers：a pilot clinical trial [J]. J Alzheimers Dis，2017，57（4）：1325-1334.
[21] Mustapic M，Tran J，Craft S，et al. Extracellular vesicle biomarkers track cognitive changes following intranasal insulin in Alzheimer’s disease [J]. J Alzheimers Dis，2019，69（2）：489-498.
[22] Sluggett JK，Koponen M，Bell JS，et al. Metformin and risk of Alzheimer’s disease among community-dwelling people with diabetes：a national case-control study [J]. J Clin Endocrinol Metab，2020，105（4）：dgz234.
[23] Yang S，Chen Z，Cao M，et al. Pioglitazone ameliorates Aβ42 deposition in rats with diet-induced insulin resistance associated with AKT/GSK3β activation [J]. Mol Med Rep，2017，15（5）：2588-2594.
[24] 郭伟，李伟，彭聪，等.西格列汀对2型糖尿病患者轻度认知功能障碍的影响[J].武汉大学学报（医学版），2021， 42（1）：123-127.
[25] Salles GN，Calió ML，Holscher C，et al. Neuroprotective and restorative properties of the GLP-1/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimer’s disease [J]. Neuropharmacology，2020，162：107813.
[26] Papazafiropoulou AK，Koros C，Melidonis A，et al. Diabetes and dementia-the two faces of Janus [J]. Arch Med Sci Atheroscler Dis，2020，5：e186-e197.
